Literature DB >> 31865539

The role of driver mutations in myeloproliferative neoplasms: insights from mouse models.

Kotaro Shide1.   

Abstract

High frequency of JAK2V617F or CALR exon 9 mutations is a main molecular feature of myeloproliferative neoplasms (MPNs). Analysis of mouse models driven by these mutations suggests that they are a direct cause of MPNs and that the expression levels of the mutated genes define the disease phenotype. The function of MPN-initiating cells has also been elucidated by these mouse models. Such mouse models also play an important role in modeling disease to investigate the effects and action mechanisms of therapeutic drugs, such as JAK2 inhibitors and interferon α, against MPNs. The mutation landscape of hematological tumors has already been clarified by next-generation sequencing technology, and the importance of functional analysis of mutant genes in vivo should increase further in the future.

Entities:  

Keywords:  CALR; JAK2; Mouse models; Myeloproliferative neoplasms

Mesh:

Substances:

Year:  2019        PMID: 31865539     DOI: 10.1007/s12185-019-02803-x

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  66 in total

1.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Authors:  Claire Harrison; Jean-Jacques Kiladjian; Haifa Kathrin Al-Ali; Heinz Gisslinger; Roger Waltzman; Viktoriya Stalbovskaya; Mari McQuitty; Deborah S Hunter; Richard Levy; Laurent Knoops; Francisco Cervantes; Alessandro M Vannucchi; Tiziano Barbui; Giovanni Barosi
Journal:  N Engl J Med       Date:  2012-03-01       Impact factor: 91.245

2.  A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors:  Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal:  Nature       Date:  2005-04-28       Impact factor: 49.962

3.  Characterization of murine JAK2V617F-positive myeloproliferative disease.

Authors:  Thomas G P Bumm; Collin Elsea; Amie S Corbin; Marc Loriaux; Daniel Sherbenou; Lisa Wood; Jutta Deininger; Richard T Silver; Brian J Druker; Michael W N Deininger
Journal:  Cancer Res       Date:  2006-12-01       Impact factor: 12.701

4.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

5.  Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.

Authors:  Shannon Elf; Nouran S Abdelfattah; Edwin Chen; Javier Perales-Patón; Emily A Rosen; Amy Ko; Fabian Peisker; Natalie Florescu; Silvia Giannini; Ofir Wolach; Elizabeth A Morgan; Zuzana Tothova; Julie-Aurore Losman; Rebekka K Schneider; Fatima Al-Shahrour; Ann Mullally
Journal:  Cancer Discov       Date:  2016-03-07       Impact factor: 39.397

6.  Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.

Authors:  Ann Mullally; Claudia Bruedigam; Luke Poveromo; Florian H Heidel; Amy Purdon; Therese Vu; Rebecca Austin; Dirk Heckl; Lawrence J Breyfogle; Catherine Paine Kuhn; Demetrios Kalaitzidis; Scott A Armstrong; David A Williams; Geoff R Hill; Benjamin L Ebert; Steven W Lane
Journal:  Blood       Date:  2013-03-13       Impact factor: 22.113

7.  Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Taghi Manshouri; Rajyalakshmi Luthra; Zeev Estrov; Sherry Pierce; Mary Ann Richie; Gautam Borthakur; Marina Konopleva; Jorge Cortes; Srdan Verstovsek
Journal:  J Clin Oncol       Date:  2009-10-13       Impact factor: 44.544

Review 8.  Mouse models of myeloproliferative neoplasms: JAK of all grades.

Authors:  Juan Li; David G Kent; Edwin Chen; Anthony R Green
Journal:  Dis Model Mech       Date:  2011-05       Impact factor: 5.758

9.  MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.

Authors:  Yana Pikman; Benjamin H Lee; Thomas Mercher; Elizabeth McDowell; Benjamin L Ebert; Maricel Gozo; Adam Cuker; Gerlinde Wernig; Sandra Moore; Ilene Galinsky; Daniel J DeAngelo; Jennifer J Clark; Stephanie J Lee; Todd R Golub; Martha Wadleigh; D Gary Gilliland; Ross L Levine
Journal:  PLoS Med       Date:  2006-07       Impact factor: 11.069

10.  JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease.

Authors:  Juan Li; David G Kent; Anna L Godfrey; Harriet Manning; Jyoti Nangalia; Athar Aziz; Edwin Chen; Kourosh Saeb-Parsy; Juergen Fink; Rachel Sneade; Tina L Hamilton; Dean C Pask; Yvonne Silber; Xiaodong Zhao; Cedric Ghevaert; Pentao Liu; Anthony R Green
Journal:  Blood       Date:  2014-04-01       Impact factor: 22.113

View more
  1 in total

1.  Crucial role of hematopoietic JAK2 V617F in the development of aortic aneurysms.

Authors:  Tetsuro Yokokawa; Tomofumi Misaka; Yusuke Kimishima; Kento Wada; Keiji Minakawa; Koichi Sugimoto; Takafumi Ishida; Soji Morishita; Norio Komatsu; Kazuhiko Ikeda; Yasuchika Takeishi
Journal:  Haematologica       Date:  2021-07-01       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.